

# Unlocking Value in Healthcare Delivery Channels

QI ZHANG & MUCHING ZHANG

MAY 25, 2017

# Table of Contents

- ▶ Market Landscape
  - ▶ Changes: Top Down and Bottom Up
  - ▶ Competitor Case Studies
  - ▶ Evidence Base
- ▶ Thesis Scope and Context
- ▶ Model & Results
  - ▶ Model Framework
  - ▶ Analysis & Results
  - ▶ Next Steps

# Patients are going outside traditional channels for their healthcare needs...

## Zipdrug and PillPack



### Pre-sorted Pills

We package your prescriptions and OTCs by the dose. Each packet is labeled with the date and time based on when you take them.

### As-needed Meds


If you have medication you don't take on a regular schedule, we'll send it in a separate bottle.

### Medications of All Types

We'll send inhalers, creams, and even refrigerated items like insulin. Need a special item? Just give us a call.

### Discreet Packaging

Our secure and unmarked box means you don't have to worry about theft or tampering.




BLINK-HEALTH

Search for a medication



Testimonials

## Get the free app



# ...and so is Big Pharma

## Merck

- ▶ Partner with Aetna Care for patients with diabetes and hypertension; Geisinger Health System for an EHR and wellness app

AstraZeneca introduced “Symbicort Maintenance and Reliever Therapy” (asthma)

Pfizer UK partnered with NHS Direct to implement a telemedicine intervention from 2005-2013

- ▶ **27% reduction in utilization and 22% reduction in cost** of secondary care (Nymark et al, 2013)

## Teva

- ▶ Shared Solutions platform for Copaxone (MS drug)
- ▶ Manufacturer-provided patient support programs improve adherence (40% more likely to be adherent after training on management of disease)
- ▶ 2014 **“Brand of the Year”**

# Patients benefit from value-added services, including home delivery

- ▶ Iyengar et al, 2010: “beneficiaries who use home delivery ... have **a greater likelihood of being adherent** than patients who fill their prescriptions at retail.”
- ▶ Moore et al, 2015: “The study demonstrated significant **improvement in both adherence to therapy and first-fill persistence** among patients in the new service model ...”
- ▶ Zuidema, et al (2015): “The most important support needs ... are more **informational, social and practical support and emotional support.** ”
- ▶ Cabrera-León et al., 2012: “direct services are **cost-effective**”

# Context & Scope

## Key Research Questions:

- ▶ What are the key cost drivers for our current distribution model?
- ▶ How will these change with the volume growth we expect?
- ▶ How will these change if alternative channels were to be implemented?

## Scope

- ▶ Market Focus: U.S.
- ▶ Product Characteristics: 1 SKU that is highly specialized, low-volume, high-value, chronic medication
- ▶ SC Focus: From receipt at own DC to distribution customer (wholesaler, etc) DC

# Model Framework – Customer Segmentation

Wholesalers (90%)

W1

W2

W3


Distributors (10%)

Large


Medium

Small

Individuals (0%)




# Model Framework – CTS Modules






# Current CTS



# Scenario Testing – Future Outlook

## Revenue Outlook 2016-2020



## CTS per unit Outlook 2016-2020




# Scenario Testing – Alternative Distribution

## Revenue Outlook With Alternative Distribution




## CTS Outlook With Alternative Distribution



# Limitations of the Model

- ▶ Aggregated Calculations
  - ▶ Does not consider seasonality or change in purchasing pattern
- ▶ Does not consider Capital Investments
- ▶ Does not consider effect on demand
  - ▶ Ex. Will going direct increase market share and lead to more sales volume?
- ▶ Does not consider response of other stakeholder parties
  - ▶ Ex. How will the wholesalers respond to going to direct?

# Discussions & Future Direction



Q & A